• June 21, 2017
    MTI Appoints David Chang as New CEO
    Metabolomic Technologies Inc. announces that it has appointed David Chang as Chief Executive Officer as of May 1st, 2017. Dr. Chang replaces Reg Joseph as CEO. He brings to the position 15 years experience managing SMEs and commercializing research projects. As the previous Chief Operating Officer of MTI, Dr. Chang oversaw the development of PolypDx™ from the research lab to market, and has established MTI as a respected and award-winning innovator.
  • June 6, 2017
    MTI Recipient of the 2017 ATB Catalyst Export Award
    On June 6, 2017 MTI was presented with the 2017 ATB Catalyst Export Award. The award recognizes MTI's engagement in international business and export, while achieving excellence through sustainable growth and innovation.
  • May 5, 2017
    MTI Launches New Product Website -
    MTI is pleased to announce the launch of a new product website for our flagship product, PolypDx™. This website will provide important education and information on PolypDx™ for both patients and healthcare professionals, as we expand coverage of PolypDx™ in the US and worldwide.
  • May 6 to 9, 2017
    MTI to Exhibit at DDW - May 2017 in Chicago, IL
    MTI is excited to be attending the 2017 Digestive Disease Week Conference, May, 2017 in Chicago, IL. Team members will be on site ready to discuss our non-invasive urine-based diagnostic test for detection of adenomatous polyps, PolypDx™. Come check us out at Booth #1612 in the New Exhibitor Pavillion Area! 
  • March 25, 2017
    MTI's Chief Operating Officer, Dr. David Chang - 2017 Canadian Medtech Mission to China
    From March 20 to 23, 2017, MTI's Dr. David Chang travelled to Beijing and Tianjin, China, as part of a delegation of medical device companies from Canada. PolypDx™ was featured as a leading potential diagnostic for the Chinese market. The Canadian mission was highlighted in this Beijing news piece on March 23, 2017 - Canadian Medical Companies Visit Beijing.
  • February 9, 2017
    MTI Granted Patent for PolypDx™ in Australia
    In early February, 2017, Metabolomic Technologies Inc. was granted a patent for its PolypDx™ technology by the Australian Patent Office. PolypDx™ received patent approval in Japan in September, 2015. Patents are also pending in the US, Canada, and Europe.
  • January 23, 2017
    MTI Signs Muti-Year, Non-Exclusive Licensing and Distribution Agreement with U.S. Based Evolution Laboratories in Association with Lab Express, LLC 
    MTI has signed a multi-year, non-exclusive licensing and distribution agreement with U.S. based Evolution Laboratories for its flagship product, PolypDx™, a urine-based diagnostic test for detection of adenomatous polyps, the precursor to colorectal cancer. This agreement marks the second licensing and distribution secured by MTI in the last year. The non-exclusive licensing and distribution agreement signed between MTI and Evolution Laboratories in association with Lab Express, LLC, provides additional entry points into five western U.S. states including; Nevada, California, Arizona, Utah and Texas. 
  • June 27, 2016
    Atlantic Diagnostic Laboratories Launches Revolutionary Urine-Based Diagnostic Test to Detect Precursor to Colon Cancer
    Atlantic Diagnostic Laboratories (ADL), today announced the official launch of PolypDx™, a non-invasive urine-based diagnostic test for detection of adenomatous polyps, the precurser to colorectal cancer. "ADL, with it's extensive LC/MS/MS expertise, is very excited to be offering the PolypDx™ non-invasive urine test for its official launch into America," said Aaron Domenico, Chief Operating Officer of ADL. "Colorectal cancer is a leading cause of death in the United States. With early detection in the adenamatous polyp stage, this form of cancer is preventable."